# Nuclide record ac-225-fpi-2068 (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/ac-225-fpi-2068/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "ac-225-fpi-2068" ;
  schema:name "Actinium-225 FPI-2068"@en ;
  schema:alternateName "225Ac-FPI-2068"@en, "[225Ac]-FPI-2068"@en ;
  schema:description "An antibody engineered to grab onto two markers found together on some solid tumours, but not on healthy cells, carries a powerful short-range radioactive payload into the tumour to try to destroy it."@en ;
  schema:url <https://nuclide.cc/drugs/ac-225-fpi-2068/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://fusionpharma.com/wp-content/uploads/2023/10/2068_AACR-poster_2023_Final.pdf>, <https://www.pharmaceutical-technology.com/news/fusion-fda-ind-fpi-2068/>, <https://clinicaltrials.gov/study/NCT06147037> ;
  nuclide:status "phase-1" ;
  nuclide:tag "alpha therapy", "bispecific antibody", "EGFR", "cMET", "actinium-225", "phase 1" ;
  nuclide:modality "alpha therapy" ;
  nuclide:related <https://nuclide.cc/drugs/fpi-2265/>, <https://nuclide.cc/isotopes/in-111/>, <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:companies <https://nuclide.cc/companies/fusion-pharma/>, <https://nuclide.cc/companies/astrazeneca/> .